Chemoradiotherapy for colorectal cancer.
作者信息
Andre N, Schmiegel W
机构信息
Medizinische Universitätsklinik, Knappschaftskrankenhaus, In der Schornau 23-25, D-44892 Bochum, Germany.
出版信息
Gut. 2005 Aug;54(8):1194-202. doi: 10.1136/gut.2004.062745.
Abstract
摘要
相似文献
1
Chemoradiotherapy for colorectal cancer.结直肠癌的放化疗
Gut. 2005 Aug;54(8):1194-202. doi: 10.1136/gut.2004.062745.
2
Adjuvant and palliative treatment of colorectal cancer with fluorinated pyrimidines. A pharmacological and clinical review.
Acta Chir Scand Suppl. 1981;504:1-28.
3
Colorectal cancer. Chemotherapy.
Recent Results Cancer Res. 1982;83:126-34.
4
Colorectal cancer: treatment of advanced disease.结直肠癌：晚期疾病的治疗
Cancer Treat Rev. 1998 Apr;24(2):119-31. doi: 10.1016/s0305-7372(98)90078-0.
5
Palliative treatment of rectal cancer: is radiotherapy alone a good option?直肠癌的姑息治疗：单纯放疗是一个好的选择吗？
J Gastrointest Surg. 2004 Mar-Apr;8(3):277-9. doi: 10.1016/j.gassur.2003.11.015.
6
Is there any alternative to conventional anticancer treatment? Comments to: Trustworthy alteration and improvement in adjuvant treatment of colon cancer. Ali Harlak, Atilla Soran Med Sci Monit, 2006; 12(3): RA46-52.传统抗癌治疗有其他替代方法吗？对《结肠癌辅助治疗中可靠的改变与改进》的评论。阿里·哈拉尔克，阿提拉·索兰。《医学科学监测》，2006年；12(3): RA46 - 52。
Med Sci Monit. 2006 Aug;12(8):LE16. Epub 2006 Jul 12.
7
[Palliative chemotherapy in colorectal cancer: new molecular drugs].[结直肠癌的姑息化疗：新型分子药物]
Ann Gastroenterol Hepatol (Paris). 1995 Mar-Apr;31(2):106-8.
8
Adjuvant intraportal chemotherapy for colorectal cancer.结直肠癌的辅助门静脉内化疗
Lancet. 1995 May 6;345(8958):1184. doi: 10.1016/s0140-6736(95)91017-4.
9
Cancers of the large bowel and hepatobiliary tract.大肠和肝胆道癌症。
Cancer Chemother Biol Response Modif. 2003;21:509-34. doi: 10.1016/s0921-4410(03)21024-3.
10
[Personalized systemic treatment of metastatic colorectal cancer].[转移性结直肠癌的个体化系统治疗]
Internist (Berl). 2020 Jul;61(7):699-710. doi: 10.1007/s00108-020-00808-x.
引用本文的文献
1
inhibition enhances colorectal cancer progression epidermal growth factor receptor/extracellular signal-regulated kinase pathways.抑制作用增强了表皮生长因子受体/细胞外信号调节激酶通路在结直肠癌进展中的作用。
World J Gastrointest Oncol. 2025 May 15;17(5):104686. doi: 10.4251/wjgo.v17.i5.104686.
2
Autoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers.癌症中的自身抗体：最常见癌症中其临床作用的系统评价。
Front Immunol. 2024 Aug 21;15:1455602. doi: 10.3389/fimmu.2024.1455602. eCollection 2024.
3
Regulation of Hippo/YAP axis in colon cancer progression by the deubiquitinase JOSD1.去泛素化酶JOSD1对结肠癌进展中Hippo/YAP轴的调控
Cell Death Discov. 2024 Aug 14;10(1):365. doi: 10.1038/s41420-024-02136-7.
4
Loss of monopolar spindle-binding protein 3B expression promotes colorectal cancer invasiveness by activation of target of rapamycin kinase/autophagy signaling.单极纺锤体结合蛋白3B表达缺失通过激活雷帕霉素激酶靶点/自噬信号通路促进结直肠癌侵袭。
World J Gastroenterol. 2024 Jul 14;30(26):3229-3246. doi: 10.3748/wjg.v30.i26.3229.
5
RhoB expression associated with chemotherapy response and prognosis in colorectal cancer.RhoB表达与结直肠癌的化疗反应及预后相关。
Cancer Cell Int. 2024 Feb 15;24(1):75. doi: 10.1186/s12935-024-03236-1.
6
Modulation of mitochondrial apoptosis by β2-adrenergic receptor blockage in colorectal cancer after radiotherapy: an and study.放疗后结直肠癌中β2-肾上腺素能受体阻断对线粒体凋亡的调节作用：一项[具体研究类型]研究
Am J Cancer Res. 2023 Aug 15;13(8):3741-3752. eCollection 2023.
7
Clinical relevance and prognostic role of preoperative cell-free single-stranded DNA concentrations in colorectal cancer patients.结直肠癌患者术前游离单链DNA浓度的临床相关性及预后作用
Korean J Clin Oncol. 2021 Dec;17(2):59-67. doi: 10.14216/kjco.21010. Epub 2021 Dec 31.
8
Role of AMPK in Regulation of Oxaliplatin-Resistant Human Colorectal Cancer.AMPK在奥沙利铂耐药性人类结直肠癌调控中的作用
Biomedicines. 2022 Oct 25;10(11):2690. doi: 10.3390/biomedicines10112690.
9
The comparative anti-cancer effects of krill oil and oxaliplatin in an orthotopic mouse model of colorectal cancer.磷虾油与奥沙利铂在结直肠癌原位小鼠模型中的抗癌效果比较
Nutr Metab (Lond). 2022 Mar 2;19(1):12. doi: 10.1186/s12986-022-00646-8.
10
Transketolase promotes colorectal cancer metastasis through regulating AKT phosphorylation.转酮醇酶通过调节 AKT 磷酸化促进结直肠癌转移。
Cell Death Dis. 2022 Feb 2;13(2):99. doi: 10.1038/s41419-022-04575-5.
本文引用的文献
1
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer.厄洛替尼（OSI - 774）用于转移性结直肠癌患者的II期研究。
Br J Cancer. 2006 Apr 24;94(8):1136-43. doi: 10.1038/sj.bjc.6603055.
2
Cancer incidence and mortality in Europe, 2004.2004年欧洲的癌症发病率和死亡率
Ann Oncol. 2005 Mar;16(3):481-8. doi: 10.1093/annonc/mdi098. Epub 2005 Feb 17.
3
Cancer statistics, 2005.2005年癌症统计数据。
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30. doi: 10.3322/canjclin.55.1.10.
4
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.原发性结直肠癌肿瘤中的表皮生长因子受体（EGFR）状态与相关转移部位的EGFR表达不相关：对EGFR靶向单克隆抗体治疗的启示。
J Clin Oncol. 2004 Dec 1;22(23):4772-8. doi: 10.1200/JCO.2004.00.117.
5
Preoperative versus postoperative chemoradiotherapy for rectal cancer.直肠癌术前与术后放化疗对比
N Engl J Med. 2004 Oct 21;351(17):1731-40. doi: 10.1056/NEJMoa040694.
6
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.伊立替康、持续输注5-氟尿嘧啶和亚叶酸（FOLFIRI）联合厄洛替尼（OSI-774）的I期试验：因毒性增加提前终止。
Clin Cancer Res. 2004 Oct 1;10(19):6522-7. doi: 10.1158/1078-0432.CCR-04-0746.
7
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.西妥昔单抗单药治疗及西妥昔单抗联合伊立替康治疗伊立替康难治性转移性结直肠癌。
N Engl J Med. 2004 Jul 22;351(4):337-45. doi: 10.1056/NEJMoa033025.
8
Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130.结肠癌手术辅助治疗中辅助化疗与放疗联合与单纯化疗的Ⅲ期研究：组间方案0130的结果
J Clin Oncol. 2004 Aug 15;22(16):3277-83. doi: 10.1200/JCO.2004.01.029. Epub 2004 Jul 12.
9
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.美国临床肿瘤学会关于II期结肠癌辅助化疗的建议。
J Clin Oncol. 2004 Aug 15;22(16):3408-19. doi: 10.1200/JCO.2004.05.063. Epub 2004 Jun 15.
10
Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group.II期结肠癌的辅助治疗：安大略癌症护理计划循证护理胃肠癌疾病部位组的系统评价
J Clin Oncol. 2004 Aug 15;22(16):3395-407. doi: 10.1200/JCO.2004.03.087. Epub 2004 Jun 15.
Zotero 插件